Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Ojara F, Henrich A, Frances N, Nassar Y, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Jörger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725.
Feb 27, 2023A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Feb 27, 2023CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725
Ojara Francis Williams, Henrich Andrea, Frances Nicolas, Nassar Yomna M, Huisinga Wilhelm, Hartung Niklas, Geiger Kimberly, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study.
Messerich N, Uda N, Volken T, Cogliatti S, Lehmann T, Holbro A, Benz R, Graf L, Gupta V, Jochum W, Demmer I, Rao T, Silzle T. CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study. Cancers (Basel) 2023; 15
Feb 25, 2023CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study.
Feb 25, 2023Cancers (Basel) 2023; 15
Messerich Nora-Medea, Uda Narasimha Rao, Volken Thomas, Cogliatti Sergio B., Lehmann Thomas, Holbro Andreas, Benz Rudolf, Graf Lukas, Gupta Vikas, Jochum Wolfram, Demmer Izadora, Rao Tata Nageswara, Silzle Tobias
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci 2023; 50:57-60.
Feb 20, 2023The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Feb 20, 2023Eur Urol Open Sci 2023; 50:57-60
Fischer Stefanie, Rothermundt Christian, Stalder Odile, Terbuch Angelika, Hermanns Thomas, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Seifert Bettina, Alex Kluth Luis, Ufe Mark-Peter, Mingrone Walter, Templeton Arnoud J, Fischer Natalie Fischer, Rothschild Sacha I, Woelky Regina, Gillessen Silke, Cathomas Richard
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Jörger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Invest New Drugs 2023; 41:267-275.
Feb 16, 2023Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Feb 16, 2023Invest New Drugs 2023; 41:267-275
Jörger Markus, Hundsberger Thomas, Haefliger Simon, von Moos Roger, Hottinger Andreas F, Kaindl Thomas, Engelhardt Marc, Marszewska Michalina, Lane Heidi, Roth Patrick, Stathis Anastasios
HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.
Zděblová Čermáková Z, Hurník P, Konvalinka D, Štembírek J, Paračková T, Resová K, Cvek J, Blažek T, Knybel L, Formánek M, Gachechiladze M, Jörger M, Soltermann A, Škarda J, Motyka O, Janoutová J. HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. Medicina (Kaunas) 2023; 59
Feb 14, 2023HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.
Feb 14, 2023Medicina (Kaunas) 2023; 59
Zděblová Čermáková Zuzana, Hurník Pavel, Konvalinka David, Štembírek Jan, Paračková Tereza, Resová Kamila, Cvek Jakub, Blažek Tomáš, Knybel Lukáš, Formánek Martin, Gachechiladze Mariam, Jörger Markus, Soltermann Alex, Škarda Jozef, Motyka Oldřich, Janoutová Jana
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Çakar E, Oniangue-Ndza C, Schneider R, Klijn S, Vogl U, Rothermundt C, May J. Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. Pharmacoecon Open 2023
Feb 9, 2023Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Feb 9, 2023Pharmacoecon Open 2023
Çakar Esra, Oniangue-Ndza César, Schneider Ralph P, Klijn Sven L, Vogl Ursula M, Rothermundt Christian, May Jessica R
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance J, González-Del-Alba A, Delgado M, Nolè F, Turco F, Mestre R, Ribi K, Cathomas R. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). J Clin Oncol 2023; 41:3608-3615.
Feb 8, 2023Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
Feb 8, 2023J Clin Oncol 2023; 41:3608-3615
Gillessen Silke, Procopio Giuseppe, Hayoz Stefanie, Kremer Eloïse, Schwitter Michael, Caffo Orazio, Lorente David, Pedrazzini Augusto, Roubaud Guilhem, Nenan Soazig, Omlin Aurelius, Buttigliero Consuelo, Delgado Mingorance Juan Ignacio, González-Del-Alba Aránzazu, Delgado Maria Teresa, Nolè Franco, Turco Fabio, Mestre Ricardo Pereira, Ribi Karin, Cathomas Richard
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz M, Shimizu C, Huang C, Lueck H, Beith J, Tokunaga E, Contreras J, de Sant'Ana R, Wei R, Shahir A, Nabinger S, Forrester T, Johnston S, Harbeck N. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Ther Adv Med Oncol 2023; 15:17588359231151840.
Feb 3, 2023Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Feb 3, 2023Ther Adv Med Oncol 2023; 15:17588359231151840
Paluch-Shimon Shani, Neven Patrick, Huober Jens, Cicin Irfan, Goetz Matthew P, Shimizu Chikako, Huang Chiun-Sheng, Lueck Hans Joachim, Beith Jane, Tokunaga Eriko, Contreras Jessica Reyes, de Sant'Ana Rosane Oliveira, Wei Ran, Shahir Ashwin, Nabinger Sarah C, Forrester Tammy, Johnston Stephen R D, Harbeck Nadia
Laser Interstitial Thermal Therapy for Radionecrosis.
Terrapon A, Krüger M, Hundsberger T, Neidert M, Bozinov O. Laser Interstitial Thermal Therapy for Radionecrosis. Neurosurg Clin N Am 2023; 34:209-225.
Jan 31, 2023Laser Interstitial Thermal Therapy for Radionecrosis.
Jan 31, 2023Neurosurg Clin N Am 2023; 34:209-225
Terrapon Alexis Paul Romain, Krüger Marie Therese, Hundsberger Thomas, Neidert Marian Christoph, Bozinov Oliver
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Di Cosimo S, Ciniselli C, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez H, Iorio M, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Front Oncol 2023; 12:1028825.
Jan 31, 2023End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Jan 31, 2023Front Oncol 2023; 12:1028825
Di Cosimo Serena, Ciniselli Chiara M, Pizzamiglio Sara, Cappelletti Vera, Silvestri Marco, El-Abed Sarra, Izquierdo Miguel, Bajji Mohammed, Nuciforo Paolo, Huober Jens, Cameron David, Chia Stephen, Gomez Henry L, Iorio Marilena V, Vingiani Andrea, Pruneri Giancarlo, Verderio Paolo
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown L, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller-Hübenthal B, Jochum W, Bonnefoi H, Martino S, Davidson N, Geyer C, Chia S, Ingle J, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates A, Goldhirsch A, Fleming G, Francis P, Speed T, Regan M, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 2023; 34:397-409.
Jan 25, 2023Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Jan 25, 2023Ann Oncol 2023; 34:397-409
Luen Stephen J, Viale Giuseppe, Nik-Zainal S, Savas Peter, Kammler Roswitha, Dell'Orto Patrizia, Biasi Olivia Maria, Degasperi A, Brown Louise C, Láng István, MacGrogan Gaëtan, Tondini Carlo, Bellet Meritxell, Villa F, Bernardo A, Ciruelos Eva, Karlsson Per, Neven Patrick, Climent Miguel A, Müller-Hübenthal Boris, Jochum Wolfram, Bonnefoi Hervé R, Martino Silvana, Davidson Nancy E, Geyer Charles E, Chia S K, Ingle James N, Coleman Robert E, Solbach Christine, Thürlimann Beat, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Fleming Gini F, Francis Prudence A, Speed T P, Regan Meredith M, Loi Sherene
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Palmerini E, Gambarotti M, Italiano A, Nathenson M, Ratan R, Dileo P, Provenzano S, Jones R, DuBois S, Martin-Broto J, de Alava E, Baldi G, Grignani G, Ferraresi V, Brunello A, Paoluzzi L, Bertulli R, Hindi N, Montemurro M, Rothermundt C, Cocchi S, Salguero-Aranda C, Donati D, Martin J, Abdelhamid Ahmed A, Mazzocca A, Carretta E, Cesari M, Pierini M, Righi A, Sbaraglia M, Laginestra M, Scotlandi K, Dei Tos A, Ibrahim T, Stacchiotti S, Vincenzi B. A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). Eur J Cancer 2023; 183:11-23.
Jan 18, 2023A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Jan 18, 2023Eur J Cancer 2023; 183:11-23
Palmerini Emanuela, Gambarotti Marco, Italiano Antoine, Nathenson Michael J, Ratan Ravin, Dileo Palma, Provenzano Salvatore, Jones Robin L, DuBois Steven G, Martin-Broto Javier, de Alava Enrique, Baldi Giacomo G, Grignani Giovanni, Ferraresi Virginia, Brunello Antonella, Paoluzzi Luca, Bertulli Rossella, Hindi Nadia, Montemurro Michael, Rothermundt Christian, Cocchi Stefania, Salguero-Aranda Carmen, Donati Davide, Martin Juan D, Abdelhamid Ahmed Amr H, Mazzocca Alessandro, Carretta Elisa, Cesari Marilena, Pierini Michela, Righi Alberto, Sbaraglia Marta, Laginestra Maria A, Scotlandi Katia, Dei Tos Angelo P, Ibrahim Toni, Stacchiotti Silvia, Vincenzi Bruno
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
Jan 12, 2023Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Jan 12, 2023Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Gomez H, Gombos A, Coccia-Portugal M, Tseng L, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer 2022; 181:92-101.
Dec 27, 2022Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Dec 27, 2022Eur J Cancer 2022; 181:92-101
Nuciforo Paolo, Townend John, Piccart Martine, Fielding Shona, Gkolfi Panagiota, El-Abed Sarra, de Azambuja Evandro, Werutsky Gustavo, Bliss Judith, Moebus Volker, Colleoni Marco, Aspitia Alvaro Moreno, Gomez Henry, Gombos Andrea, Coccia-Portugal Maria Antonia, Tseng Ling-Ming, Kunz Georg, Lerzo Guillermo, Sohn Joohyuk, Semiglazov Vladimir, Saura Cristina, Kroep Judith, Ferro Antonella, Cameron David, Gelber Richard D, Huober Jens, Di Cosimo Serena
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Christiansen A, Lobo J, Fankhauser C, Rothermundt C, Cathomas R, Batavia A, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. Front Oncol 2022; 12:1056823.
Dec 8, 2022Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Dec 8, 2022Front Oncol 2022; 12:1056823
Christiansen Ailsa J, Lobo João, Fankhauser Christian D, Rothermundt Christian, Cathomas Richard, Batavia Aashil A, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Jörg, Hermanns Thomas
Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
Koster K, Zumstein V, Süveg K, Jochum W, Husarik D, Omlin A. Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer. BJU Int 2022
Dec 5, 2022Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
Dec 5, 2022BJU Int 2022
Koster Kira-Lee, Zumstein Valentin, Süveg Krisztian, Jochum Wolfram, Husarik Daniela, Omlin Aurelius
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston S, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang C, Huober J, Jaliffe G, Cicin I, Tolaney S, Goetz M, Rugo H, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martín M, ĀăąĆĉČĎ Ā. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2022
Dec 5, 2022Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Dec 5, 2022Lancet Oncol 2022
Johnston Stephen R D, Toi Masakazu, O'Shaughnessy Joyce, Rastogi Priya, Campone Mario, Neven Patrick, Huang Chiun-Sheng, Huober Jens, Jaliffe Georgina Garnica, Cicin Irfan, Tolaney Sara M, Goetz Matthew P, Rugo Hope S, Senkus Elzbieta, Testa Laura, Del Mastro Lucia, Shimizu Chikako, Wei Ran, Shahir Ashwin, Munoz Maria, San Antonio Belen, Andre Valerie, Harbeck Nadia, Martín Miguel, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ
Der Mystiker aus Nazaret
Renz M. Der Mystiker aus Nazaret - Jesuanische Spiritualität. Basel: Herder, 2022. ISBN 978-3-451-06875-1.
Dec 1, 2022Der Mystiker aus Nazaret
Dec 1, 2022Herder, ISBN 978-3-451-06875-1
Renz Monika
Von-Hippel-Lindau-Erkrankung
Koster K, Rothermundt C, Binet F, Borovicka J, Bozinov O, Clerici T, Engeler D, Greiner J, Hader C, Heinimann K, Azzarello-Burri S, Lang C, Krull I, Stöckli S, Omlin A, Hundsberger T. Von-Hippel-Lindau-Erkrankung - Interdisziplinäre Betreuung und neue therapeutische Optionen. Swiss Med Forum 2022; 48:4-784-787.
Nov 30, 2022Von-Hippel-Lindau-Erkrankung
Nov 30, 2022Swiss Med Forum 2022; 48:4-784-787
Koster Kira-Lee, Rothermundt Christian, Binet Françoise-Isabelle, Borovicka Jan, Bozinov Oliver, Clerici Thomas, Engeler Daniel, Greiner J, Hader Claudia, Heinimann Karl, Azzarello-Burri Silvia, Lang Corina, Krull Ina, Stöckli Sandro, Omlin Aurelius, Hundsberger Thomas
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. Breast Cancer Res Treat 2022
Nov 21, 2022Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Nov 21, 2022Breast Cancer Res Treat 2022
Huebner Hanna, Ruebner Matthias, Kurbacher Christian, Hadji Peyman, Hartkopf Andreas D, Lux Michael P, Huober Jens, Uhrig Sabrina, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Hein Alexander, Belleville Erik, Untch Michael, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Ettl Johannes, Fasching Peter A, Michel Laura L